JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study

Trial Profile

JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 May 2017

At a glance

  • Drugs Momelotinib (Primary) ; Pacritinib (Primary) ; Ruxolitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Melphalan; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 May 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 13 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top